References
- Mearin F, Lacy BE, Chang L, et al. Section II: FGIDS: diagnostic groups bowel. Gastroenterology. 2016;150(6): 1393–1407. Available from: https://www.gastrojournal.org/article/S0016-5085(16)00222-5/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F
- Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med. 2017 Oct 26; 6(11):99. https://doi.org/10.3390/jcm6110099
- Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021 Jan 1;116(1):17–44. https://doi.org/10.14309/ajg.0000000000001036.
- Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021 Jan;160(1):99–114 e3. DOI:https://doi.org/10.1053/j.gastro.2020.04.014.
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712–721 e4.
- Quigley EMM, Horn J, Kissous-Hunt M, et al. Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS-C) study: results of an online questionnaire. Adv Ther. 2018 Jul;35(7):967–980. DOI:https://doi.org/10.1007/s12325-018-0733-x.
- Drossman DA, Chang L, Schneck S, et al. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci. 2009 Jul;54(7):1532–1541. DOI:https://doi.org/10.1007/s10620-009-0792-6.
- Ballou S, McMahon C, Lee HN, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America Survey. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2471–2478 e3. DOI:https://doi.org/10.1016/j.cgh.2019.08.016.
- Tait C, Sayuk GS. The brain-gut-microbiotal axis: a framework for understanding functional GI illness and their therapeutic interventions. Eur J Intern Med. 2021 Feb;84:1–9. DOI:https://doi.org/10.1016/j.ejim.2020.12.023
- Keszthelyi D, Troost FJ, Simren M, et al. Revisiting concepts of visceral nociception in irritable bowel syndrome. Eur J Pain. 2012 Nov;16(10):1444–1454. DOI:https://doi.org/10.1002/j.1532-2149.2012.00147.x.
- Videlock EJ, Chang L. Latest insights on the pathogenesis of irritable bowel syndrome. Gastroenterol Clin North Am. 2021 Sep;50(3):505–522.
- Tornkvist NT, Aziz I, Whitehead WE, et al. Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European Gastroenterol J. 2021 Oct 1 9(10):1178–1188. https://doi.org/10.1002/ueg2.12153
- Barberio B, Savarino EV, Black CJ, et al. Placebo response rates in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: meta-analysis. Clin Gastroenterol Hepatol. 2021 Aug 20;https://doi.org/10.1016/j.cgh.2021.08.025
- Sayuk GS. Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints. Am J Gastroenterol. 2012 Nov;107(11):1726–1729.
- Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil. 2013 Jun;25(6):453–457. DOI:https://doi.org/10.1111/nmo.12151.
- Chang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005 Jan;100(1):115–123. DOI:https://doi.org/10.1111/j.1572-0241.2005.40365.x.
- Baker DE. Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7(Suppl 3):S11–8.
- Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl. 1987;130(sup130):81–84.
- Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6 364(1):22–32. https://doi.org/10.1056/NEJMoa1004409
- Pimentel M, Cash BD, Lembo A, et al. Repeat Rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity. Dig Dis Sci. 2017 Sep;62(9):2455–2463. DOI:https://doi.org/10.1007/s10620-017-4598-7.
- Shah E, Kim S, Chong K, et al. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med. 2012 Apr;125(4):381–393. DOI:https://doi.org/10.1016/j.amjmed.2011.08.026.
- Wade PR, Palmer JM, McKenney S, et al. Modulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist/ micro opioid receptor antagonist. Br J Pharmacol. 2012 Nov;167(5):1111–1125. DOI:https://doi.org/10.1111/j.1476-5381.2012.02068.x.
- Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016 Jan 21 374(3):242–253. https://doi.org/10.1056/NEJMoa1505180
- Brenner DM, Sayuk GS, Gutman CR, et al. Efficacy and safety of eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with loperamide: RELIEF phase 4 study. Am J Gastroenterol. 2019 Sep;114(9):1502–1511. DOI:https://doi.org/10.14309/ajg.0000000000000327.
- Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol. 2007 Aug;102(8):1709–1719. DOI:https://doi.org/10.1111/j.1572-0241.2007.01282.x.
- Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001 Sep;96(9):2662–2670. DOI:https://doi.org/10.1111/j.1572-0241.2001.04128.x.
- Lotronex (alosetron hydrochloride) Information [11/June/2021]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/lotronex-alosetron-hydrochloride-information
- Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009 Feb 1 29(3):329–341. https://doi.org/10.1111/j.1365-2036.2008.03881.x
- Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012 Mar;35(5):587–599. DOI:https://doi.org/10.1111/j.1365-2036.2011.04983.x.
- Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3’,5’-monophosphate. Gastroenterology. 2013 Dec;145(6):1334–46 e1-11. DOI:https://doi.org/10.1053/j.gastro.2013.08.017.
- Fortejr LR Jr. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther. 2004 Nov;104(2):137–162.
- Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010 Dec;139(6):1877–1886 e2. DOI:https://doi.org/10.1053/j.gastro.2010.08.041.
- Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012 Nov;107(11):1702–1712. DOI:https://doi.org/10.1038/ajg.2012.254.
- Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012 Nov;107(11):1714–24. DOI:https://doi.org/10.1038/ajg.2012.255.
- Guidance for Industry Irritable Bowel Syndrome —Clinical Evaluation of Drugs for Treatment [11/6/2021]. [cited 2022 Mar 1]. Available from: https://www.fda.gov/media/78622/download
- Lacy BE, Brenner DM, Chey WD. Re-evaluation of the cardiovascular safety profile of tegaserod: a review of the clinical data. Clin Gastroenterol Hepatol. 2021 May 25. https://doi.org/10.1016/j.cgh.2021.05.040
- Shah ED, Lacy BE, Chey WD, et al. Tegaserod for irritable bowel syndrome with constipation in women younger than 65 years without cardiovascular disease: pooled analyses of 4 controlled trials. Am J Gastroenterol. 2021 Aug 1 116(8):1601–1611. https://doi.org/10.14309/ajg.0000000000001313
- Li Q, King A, Liu L, et al. Tenapanor reduces IBS pain through inhibition of TRPV1-dependent neuronal hyperexcitability in vivo. Am J Gastroenterol. 2017;112:2255.
- Chey WD, Lembo AJ, Yang Y, et al. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). Am J Gastroenterol. 2021 Jun 1 116(6):1294–1303. https://doi.org/10.14309/ajg.0000000000001056
- Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. Am J Gastroenterol. 2017 May;112(5):763–774.
- Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018 Dec;155(6):1753–1763.
- Black CJ, Burr NE, Ford AC. Relative efficacy of tegaserod in a systematic review and network meta-analysis of licensed therapies for irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol. 2020 May;18(5):1238–1239 e1.
- O’Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract. 1999 Dec;48(12):980–990.
- Jackson JL, O’Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000 Jan;108(1):65–72. DOI:https://doi.org/10.1016/S0002-9343(99)00299-5.
- Clouse RE, Lustman PJ. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut. 2005 Sep;54(9):1332–1341.
- Drossman DA, Tack J, Ford AC, et al. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation Working Team report. Gastroenterology. 2018 Mar;154(4):1140–1171 e1. DOI:https://doi.org/10.1053/j.gastro.2017.11.279.
- Ford AC, Lacy BE, Harris LA, et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019 Jan;114(1):21–39. DOI:https://doi.org/10.1038/s41395-018-0222-5.
- Tornblom H, Drossman DA. Psychopharmacologic therapies for irritable bowel syndrome. Gastroenterol Clin North Am. 2021 Sep;50(3):655–669.
- Palsson OS, Whitehead W, Tornblom H, et al. Prevalence of rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020 Apr;158(5):1262–1273 e3. DOI:https://doi.org/10.1053/j.gastro.2019.12.021.
- Aad G, Abajyan T, Abbott B, et al. Search for magnetic monopoles in sqrt[s]=7 TeV pp collisions with the ATLAS detector. Phys Rev Lett. [2012 Dec 28];109(26):261803.
- Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014 Nov;40(9):1023–1034.
- Chandar AK. Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide. Int J Gen Med. 2017;10:385–393.
- Sayuk GS, Wolf R, Chang L. Comparison of symptoms, healthcare utilization, and treatment in diagnosed and undiagnosed individuals with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2017 Jun;112(6):892–899.
- Gunnarsson J, Simren M. Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis. 2009 Nov;41(11):788–793.
- Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):163–173.
- Camilleri M, Vijayvargiya P. The role of bile acids in chronic diarrhea. Am J Gastroenterol. 2020 Oct;115(10):1596–1603.
- Ek WE, Reznichenko A, Ripke S, et al. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut. 2015 Nov;64(11):1774–1782. DOI:https://doi.org/10.1136/gutjnl-2014-307997.
- Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003 Jul;98(7):1578–1583.
- Bradford K, Shih W, Videlock EJ, et al. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol. 2012 Apr;10(4):385–90 e1-3. DOI:https://doi.org/10.1016/j.cgh.2011.12.018.
- Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology. 2011 Mar;140(3):761–765.
- Tornblom H, Van Oudenhove L, Sadik R, et al. Colonic transit time and IBS symptoms: What’s the link? Am J Gastroenterol. 2012 May;107(5):754–760. DOI:https://doi.org/10.1038/ajg.2012.5.
- Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008 Jul;6(7):772–781. DOI:https://doi.org/10.1016/j.cgh.2008.02.060.
- Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009 Feb;58(2):196–201. DOI:https://doi.org/10.1136/gut.2007.140806.
- Camilleri M. Serotonin in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2009 Feb;16(1):53–59.
- Gershon MD, Wade PR, Kirchgessner AL, et al. 5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. Neuropsychopharmacology. 1990 Oct-Dec;3(5–6):385–395.
- Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol Motil. 2011 Mar;23(3):193–200.
- Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 2008 Aug;57(8):1140–1155.
- Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil. 2006 Oct;18(10):949–956.
- Maselli DB, Camilleri MP. Clinical effects, and therapeutic potential of cannabinoids for gastrointestinal and liver diseases. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1748–1758 e2.
- Izzo AA. The cannabinoid CB 2 receptor: a good friend in the gut. Neurogastroenterol Motil. 2007 Sep;19(9):704–708.
- Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol. 2004 Apr;141(8):1335–1345.
- Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology. 2016 Aug;151(2):252–266.
- Gotfried J, Naftali T, Schey R. Role of cannabis and its derivatives in gastrointestinal and hepatic disease. Gastroenterology. 2020 Jul;159(1):62–80.
- Oduyebo I, Camilleri M. Bile acid disease: the emerging epidemic. Curr Opin Gastroenterol. 2017 May;33(3):189–195.
- Camilleri M, Gores GJ. Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol. 2015 Aug 15; 309(4):G209–15. https://doi.org/10.1152/ajpgi.00121.2015
- Camilleri M, Nord SL, Burton D, et al. Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea. Aliment Pharmacol Ther. 2020 Sep;52(5):808–820. DOI:https://doi.org/10.1111/apt.15967.
- Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol. 2014 Jul;7(4):167–175.
- Grunkemeier DM, Cassara JE, Dalton CB, et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1126–39; quiz 1121–2. DOI:https://doi.org/10.1016/j.cgh.2007.06.013.
- Ok HG, Kim SY, Lee SJ, et al. Can oliceridine (TRV130), an ideal novel micro receptor G protein pathway selective (micro-GPS) modulator, provide analgesia without opioid-related adverse reactions? Korean J Pain. 2018 Apr;31(2):73–79. DOI:https://doi.org/10.3344/kjp.2018.31.2.73.
- Gottesman-Katz L, Latorre R, Vanner S, et al. Targeting G protein-coupled receptors for the treatment of chronic pain in the digestive system. Gut. 2021 May;70(5):970–981. DOI:https://doi.org/10.1136/gutjnl-2020-321193.
- Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159–176. DOI:https://doi.org/10.1136/gutjnl-2012-302167.
- Scanzi J, Accarie A, Muller E, et al. Colonic overexpression of the T-type calcium channel Cav 3.2 in a mouse model of visceral hypersensitivity and in irritable bowel syndrome patients. Neurogastroenterol Motil. 2016 Nov;28(11):1632–1640. DOI:https://doi.org/10.1111/nmo.12860.
- Cai S, Gomez K, Moutal A, et al. Targeting T-type/CaV3.2 channels for chronic pain. Transl Res. 2021 Aug;234:20–30.
- Imani F, Rahimzadeh P. Gabapentinoids: gabapentin and pregabalin for postoperative pain management. Anesth Pain Med. 2012;2(2):52–53. Fall. DOI:https://doi.org/10.5812/aapm.7743.
- Beckers AB, Weerts Z, Helyes Z, et al. Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome. Aliment Pharmacol Ther. 2017 Nov;46(10):938–952. DOI:https://doi.org/10.1111/apt.14294.
- Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016 Apr;150(4):875–87 e9. DOI:https://doi.org/10.1053/j.gastro.2015.12.034.
- Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002 May;3(5):383–394.
- Russell JP, Mohammadi E, Ligon CO, et al. Exploring the potential of RET kinase inhibition for irritable bowel syndrome: a preclinical investigation in rodent models of colonic hypersensitivity. J Pharmacol Exp Ther. 2019 Feb;368(2):299–307. DOI:https://doi.org/10.1124/jpet.118.252973.
- Russell JP, Mohammadi E, Ligon C, et al. Enteric RET inhibition attenuates gastrointestinal secretion and motility via cholinergic signaling in rat colonic mucosal preparations. Neurogastroenterol Motil. 2019 Apr;31(4):e13479. DOI:https://doi.org/10.1111/nmo.13479.
- Hellstrom PM, Naslund E, Edholm T, et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil. 2008 Jun;20(6):649–659. DOI:https://doi.org/10.1111/j.1365-2982.2007.01079.x.
- Li ZY, Zhang N, Wen S, et al. Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome. Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):459–465. DOI:https://doi.org/10.1016/j.clinre.2016.12.007.
- Spiller R. Inhibiting glucose absorption to treat constipation. Lancet Gastroenterol Hepatol. 2018 Sep;3(9):588–589.
- LOTRONEX (alosetron hydrochloride) Prescribing Information [11/June/2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021107s013lbl.pdf
- Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012 Sep;36(5):437–448. DOI:https://doi.org/10.1111/j.1365-2036.2012.05208.x.
- Steadman CJ, Talley NJ, Phillips SF, et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc. 1992 Aug;67(8):732–738. DOI:https://doi.org/10.1016/S0025-6196(12)60797-6.
- Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther. 1996 Aug;10(4):595–599.
- Plasse TF, Barton G, Davidson E, et al. Bimodal release ondansetron improves stool consistency and symptomatology in diarrhea-predominant irritable bowel syndrome: a randomized, double-blind, trial. Am J Gastroenterol. 2020 Sep;115(9):1466–1473. DOI:https://doi.org/10.14309/ajg.0000000000000727.
- Gunn D, Fried R, Lalani R, et al. Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. Trials. 2019 Aug 20 20(1):517. https://doi.org/10.1186/s13063-019-3562-6
- Qi Q, Zhang Y, Chen F, et al. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018 Jan 8 18(1):5. https://doi.org/10.1186/s12876-017-0734-2
- Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011 Dec;23(12):1098–1104. DOI:https://doi.org/10.1111/j.1365-2982.2011.01771.x.
- Zheng Y, Yu T, Tang Y, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12(3):e0172846. DOI:https://doi.org/10.1371/journal.pone.0172846.
- Rokkas T, Ekmektzoglou K, Niv Y. Comparative effectiveness of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a network meta-analysis of randomized controlled studies. Ann Gastroenterol. 2021 Jul-Aug;34(4):535–546.
- Shi ZC, Devasagayaraj A, Gu K, et al. Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J Med Chem. 2008 Jul 10 51(13):3684–3687. https://doi.org/10.1021/jm800338j
- Jin H, Cianchetta G, Devasagayaraj A, et al. Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors. Bioorg Med Chem Lett. 2009 Sep 1 19(17):5229–5232. https://doi.org/10.1016/j.bmcl.2009.07.005
- Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158–169. DOI:https://doi.org/10.1038/clpt.2012.58.
- Whitehead WE, Duffy K, Sharpe J, et al. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2017 Jan;45(1):14–26. DOI:https://doi.org/10.1111/apt.13839.
- Barkun AN, Love J, Gould M, et al. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Can J Gastroenterol. 2013 Nov;27(11):653–659. DOI:https://doi.org/10.1155/2013/485631.
- Vijayvargiya P, Camilleri M, Carlson P, et al. Effects of colesevelam on bowel symptoms, biomarkers, and colonic mucosal gene expression in patients with bile acid diarrhea in a randomized trial. Clin Gastroenterol Hepatol. 2020 Dec;18(13):2962–2970 e6. DOI:https://doi.org/10.1016/j.cgh.2020.02.027.
- Zhang JH, Nolan JD, Kennie SL, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol. 2013 May 15 304(10):G940–8. https://doi.org/10.1152/ajpgi.00398.2012
- Pellicciari R, Costantino G, Camaioni E, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem. 2004 Aug 26 47(18):4559–4569. https://doi.org/10.1021/jm049904b
- Walters JR, Johnston IM, Nolan JD, et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther. 2015 Jan;41(1):54–64. DOI:https://doi.org/10.1111/apt.12999.
- Schenck Eidam H, Russell J, Raha K, et al. Discovery of a first-in-class gut-restricted RET kinase inhibitor as a clinical candidate for the treatment of IBS. ACS Med Chem Lett. 2018 Jul 12 9(7):623–628. https://doi.org/10.1021/acsmedchemlett.8b00035
- Lembo A, Steinberg F, Sanders V, et al. PHASE 1 RESULTS OF ORP-101, A NOVEL PARTIAL µ AGONIST, FULL κ ANTAGONIST WITHOUT OPIOID-LIKE ADVERSE EFFECTS, WHICH IS BEING DEVELOPED TO TREAT IBS-D. Gastroenterology. 2020;158(6):S853–4. DOI:https://doi.org/10.1016/S0016-5085(20)32811-0.
- Hoy SM. Rifamycin SV MMX((R)): a review in the treatment of traveller’s diarrhoea. Clin Drug Investig. 2019 Jul;39(7):691–697.
- COSMO ANNOUNCES SUCCESSFUL OUTCOME OF RIFAMYCIN 600MG PHASE II TRIAL IN IBS-D [11/June/2021]. Available from: https://www.cosmopharma.com/news-and-media/news-releases/2021/210111
- Tsubouchi T, Kunimatsu T, Tsujimoto S, et al. The in vitro pharmacology and non-clinical cardiovascular safety studies of a novel 5-HT4 receptor agonist, DSP-6952. Eur J Pharmacol. 2018 May 5;826:96–105. https://doi.org/10.1016/j.ejphar.2018.02.037.
- Fukudo S, Nakamura M, Hamatani T, et al. Efficacy and safety of 5-HT4 receptor agonist minesapride for irritable bowel syndrome with constipation in a randomized controlled trial. Clin Gastroenterol Hepatol. 2021 Mar;19(3):538–546 e8. DOI:https://doi.org/10.1016/j.cgh.2020.03.019.
- Hamatani T, Fukudo S, Nakada Y, et al. Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation. Aliment Pharmacol Ther. 2020 Aug;52(3):430–441. DOI:https://doi.org/10.1111/apt.15907.
- Black CJ, Barberio B, Ford AC. Editorial: minesapride for irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2020 Aug;52(4):713–714.
- Ohno H, Kojima Y, Harada H, et al. Absorption, disposition, metabolism and excretion of [(14)C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats. Xenobiotica. 2019 Apr;49(4):463–473. DOI:https://doi.org/10.1080/00498254.2018.1449269.
- Inoue T, Takemura M, Fushimi N, et al. Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur J Pharmacol. 2017 Jul 5;806:25–31. https://doi.org/10.1016/j.ejphar.2017.04.010.
- Fukudo S, Endo Y, Hongo M, et al. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Gastroenterol Hepatol. 2018 Sep;3(9):603–613. DOI:https://doi.org/10.1016/S2468-1253(18)30165-1.
- Black CJ, Ford AC. Mizagliflozin for the Treatment of Functional Constipation: are New Drugs Better? Gastroenterology. 2019 Feb;156(3):818–820.
- Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest. 1971 Aug;50(8):1569–1577.
- Taniguchi S, Yano T, Imaizumi M, et al. Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs. Neurogastroenterol Motil. 2018 Dec;30(12):e13448. DOI:https://doi.org/10.1111/nmo.13448.
- Alemi F, Poole DP, Chiu J, et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology. 2013 Jan;144(1):145–154. DOI:https://doi.org/10.1053/j.gastro.2012.09.055.
- Vijayvargiya P, Busciglio I, Burton D, et al. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin Gastroenterol Hepatol. 2018 Apr;16(4):522–527. DOI:https://doi.org/10.1016/j.cgh.2017.06.039.
- Misawa N, Higurashi T, Takatsu T, et al. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota. Aliment Pharmacol Ther. 2020 Sep;52(5):821–828. DOI:https://doi.org/10.1111/apt.15950.
- Nakajima A, Taniguchi S, Kurosu S, et al. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: post hoc analyses of two phase 3 trials in Japan. Neurogastroenterol Motil. 2019 May;31(5):e13571. DOI:https://doi.org/10.1111/nmo.13571.
- Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Aug;3(8):537–547. DOI:https://doi.org/10.1016/S2468-1253(18)30123-7.
- Nakajima A, Seki M, Taniguchi S. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J Gastroenterol. 2018 Apr;53(4):525–534.
- Kumagai Y, Amano H, Sasaki Y, et al. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: a randomized controlled trial. Br J Clin Pharmacol. 2018 Oct;84(10):2393–2404. DOI:https://doi.org/10.1111/bcp.13698.
- Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011 Dec;106(12):2154–2164. DOI:https://doi.org/10.1038/ajg.2011.285.
- Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol. 2011 Oct;106(10):1803–1812. DOI:https://doi.org/10.1038/ajg.2011.162.
- Khanna L, Camilleri M. Review article: elobixibat: a novel treatment for chronic constipation. Aliment Pharmacol Ther. 2021 Jan;53(2):234–242.
- Hellstrom PM, Hein J, Bytzer P, et al. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther. 2009 Jan;29(2):198–206. DOI:https://doi.org/10.1111/j.1365-2036.2008.03870.x.
- Camilleri M, Vazquez-Roque M, Iturrino J, et al. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G120–8. DOI:https://doi.org/10.1152/ajpgi.00076.2012.
- Almario CV, Eberlein S, Khalil C, et al. Determining patient treatment preferences for management of acute pain episodes in irritable bowel syndrome. Neurogastroenterol Motil. 2021 Apr 2:e14145; 3312: https://doi.org/10.1111/nmo.14145
- Kerckhove N, Scanzi J, Pereira B, et al. Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome - IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial. BMJ Open. 2017 Jul 18 7(7):e015380. https://doi.org/10.1136/bmjopen-2016-015380
- Sastre J. Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience. J Investig Allergol Clin Immunol. 2020;30(3):156–168.
- Yacyshyn B, Ginsberg DC, Gilder K, et al. Safety and efficacy of Olorinab, a peripherally restricted, highly selective, Cannabinoid receptor 2 Agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s Disease. Gastroenterol. 2019;156(6):S665. DOI:https://doi.org/10.1016/S0016-5085(19)38567-1.
- ARENA PHARMACEUTICALS REPORTS TOPLINE RESULTS FROM PHASE 2B CAPTIVATE CLINICAL TRIAL [11/June/2021]. Available from: https://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-reports-topline-results-phase-2b-captivate
- Wong BS, Camilleri M, Busciglio I, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011 Nov;141(5):1638–47 e1-7. DOI:https://doi.org/10.1053/j.gastro.2011.07.036.
- Wong BS, Camilleri M, Eckert D, et al. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil. 2012 Apr;24(4):358–e169. DOI:https://doi.org/10.1111/j.1365-2982.2011.01874.x.
- Stark P. Nabilone and cancer chemotherapy. Ann Intern Med. 1982 Jan;96(1):122.
- Tsang CC, Giudice MG. Nabilone for the Management of Pain. Pharmacotherapy. 2016 Mar;36(3):273–286.
- Gale JD, Houghton LA. Alpha 2 delta (alpha(2)delta) ligands, Gabapentin and Pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome. Front Pharmacol. 2011;2:28.
- Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2005 Nov 15; 22(10):981–988. https://doi.org/10.1111/j.1365-2036.2005.02685.x
- Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 2010 Dec;35(6):639–656. DOI:https://doi.org/10.1111/j.1365-2710.2009.01144.x.
- Houghton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007 Sep;56(9):1218–1225. DOI:https://doi.org/10.1136/gut.2006.110858.
- Saito YA, Almazar AE, Tilkes KE, et al. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther. 2019 Feb;49(4):389–397. DOI:https://doi.org/10.1111/apt.15077.
- Viscusi ER, Skobieranda F, Soergel DG, et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927–943.
- Singla NK, Skobieranda F, Soergel DG, et al. APOLLO-2: a randomized, placebo and active-controlled phase iii study investigating Oliceridine (TRV130), a G Protein-biased ligand at the mu-Opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract. 2019 Sep;19(7):715–731. DOI:https://doi.org/10.1111/papr.12801.
- Singla N, Minkowitz HS, Soergel DG, et al. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res. 2017;10:2413–2424.
- Hammer GB, Khanna AK, Michalsky C, et al. Oliceridine exhibits improved tolerability compared to morphine at equianalgesic conditions: exploratory analysis from two phase 3 randomized placebo and active controlled trials. Pain Ther. 2021;10(2):1343–1353. doi:https://doi.org/10.1007/s40122-021-00299-0.
- Bergese SD, Brzezinski M, Hammer GB, et al. ATHENA: a phase 3, open-label study of the safety and effectiveness of oliceridine (trv130), a g-protein selective agonist at the micro-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy. J Pain Res. 2019;12:3113–3126.
- Jimenez-Vargas NN, Yu Y, Jensen DD, et al. Agonist that activates the micro-opioid receptor in acidified microenvironments inhibits colitis pain without side effects. Gut. 2022;71(4): 695–704. doi:https://doi.org/10.1136/gutjnl-2021-324070
- Garrigues V, Mearin F, Badia X, et al. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study). Aliment Pharmacol Ther. 2007 Feb 1 25(3):323–332. https://doi.org/10.1111/j.1365-2036.2006.03197.x
- Wong RK, Palsson OS, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol. 2010 Oct;105(10):2228–2234. DOI:https://doi.org/10.1038/ajg.2010.200.
- Evaluation of medicinal products for the treatment of irritable bowel syndrome [11/June/2021]. Available from: https://www.ema.europa.eu/en/evaluation-medicinal-products-treatment-irritable-bowel-syndrome